AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30326006
Drug: Pregabalin (PGB)
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin (PGB) 150 mg to 300 mg twice daily for 8 weeks
Trial: 23224298
Drug: COX‐2 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COX‐2 inhibitor (Celecoxib)
Trial: 19290689
Drug: Behavioral Naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Naltrexone Therapy (BNT)
Trial: 11783256
Drug: Integrated Traditional
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Traditional Chinese and Western medicine (TCM-WM)
Trial: 2009146
Drug: Delapril (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delapril (15 mg twice daily)
Trial: 2009146
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg daily, with potential doubling of dose if necessary)
Trial: 2009146
Drug: Delapril and
RxNorm normalized name: delapril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delapril and Enalapril with addition of hydrochlorothiazide (25 mg daily if target not reached)
Trial: 31912678
Drug: ddPC (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ddPC (weekly paclitaxel and 3-weekly carboplatin)
Trial: 17065166
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of morphine (0.15 mg kg(‐1))
Trial: 7942653
Drug: Cervical headgear/lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical headgear/lower utility arch combination (CHG/LUA)
Trial: 3064717
Drug: Chemotherapy (5-FU)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (5-FU)
Trial: 31791675
Drug: Ketamine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (single subanesthetic-dose intravenous infusion)
Trial: 17208413
Drug: Risperidone 6
RxNorm normalized name: risperidone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 6 mg/day plus celecoxib 400 mg/day (200 mg bid)
Trial: 11423506
Drug: Nateglinide (60,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (60, 120, or 180 mg)
Trial: 11423506
Drug: Nateglinide (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (60 mg)
Trial: 11423506
Drug: Nateglinide (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (180 mg)
Trial: 11423506
Drug: Nateglinide (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (higher doses)
Trial: 11229181
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (300 mg/day for 15 days)
Trial: 2758752
Drug: Out-patient lumbar
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Out-patient lumbar radiculography with 10 ml iohexol (240 mgI/ml)
Trial: 19966701
Drug: Minimally invasive,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive, endovascular methods of treatment
Trial: 16723553
Drug: Voriconazole at
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole at 400 mg twice daily on the first day and 200 mg twice daily on the second day
Trial: 16723553
Drug: Fluconazole at
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole at 400 mg on the first day and 200 mg on the second day
Trial: 16723553
Drug: Control (Ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Ibuprofen alone)
Trial: 11150432
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with etoposide, bleomycin, and high or standard dose cisplatin
Trial: 11150432
Drug: Biopsy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biopsy and chemotherapy without tumor resection
Trial: 11150432
Drug: Resection at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resection at diagnosis followed by chemotherapy
Trial: 11150432
Drug: Biopsy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biopsy followed by chemotherapy and post-chemotherapy tumor resection
Trial: 8121966
Drug: SSRIs (fluoxetine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs (fluoxetine, sertraline)
Trial: 3314790
Drug: 0.9 mw
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mw continuous wave HeNe laser treatment
Trial: 17626986
Drug: Nadroparin (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin (therapeutic doses throughout treatment)
Trial: 17626986
Drug: Parnaparin (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parnaparin (therapeutic doses for the first month, then prophylactic phase at half dose)
Trial: 15793400
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 2% lidocaine hydrochloride
Trial: 12606735
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg adefovir dipivoxil
Trial: 12606735
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg adefovir dipivoxil
Trial: 31310470
Drug: 0.04 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04 mg/kg lorazepam per os (PO) twice before the operation
Trial: 23520670
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no anxiolytic premedication)
Trial: 25476995
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral ibandronate
Trial: 25476995
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg i.v. ibandronate
Trial: 22251482
Drug: FBS0701 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FBS0701 at 14.5 mg/kg/d
Trial: 22251482
Drug: FBS0701 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FBS0701 at 29 mg/kg/d
Trial: 19177255
Drug: Transdermal E2/NETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2/NETA 50 microg/140 microg
Trial: 11666126
Drug: Total triterpenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total triterpenic fraction of Centella asiatica (TTFCA) at 120 mg daily
Trial: 11666126
Drug: Total triterpenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total triterpenic fraction of Centella asiatica (TTFCA) at 60 mg daily
Trial: 9579130
Drug: Abdominal wall
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abdominal wall injection of low-dose heparin
Trial: 9579130
Drug: Upper limb
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper limb injection of low-dose heparin
Trial: 28774885
Drug: MNP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNP with 5 mg iron (Fe group)
Trial: 28774885
Drug: MNP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNP with 7.5 g GOS and 5 mg iron (FeGOS group)
Trial: 23816760
Drug: S-1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 plus carboplatin; S-1 at 80 mg/m²/day for 2 weeks, followed by 2 weeks of no treatment; Carboplatin at AUC 6 on day 8, repeated for 4-6 cycles of 28 days
Trial: 16924046
Drug: 5% fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% fluorouracil cream applied twice daily for 3 weeks
Trial: 16924046
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (5 of 7 eligible patients who declined study-related treatment)
Trial: 11167663
Drug: Moxonidine (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine (0.1, 0.2, 0.3 mg twice daily)
Trial: 9042124
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period (15 minutes before and after treatment)
Trial: 2145654
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg almitrine
Trial: 2145654
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg medroxyprogesterone
Trial: 23122840
Drug: 1 IU
RxNorm normalized name: factor VIII 1 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 IU of oxytocin followed by an infusion of 2.5 UI×h(‐1)
Trial: 23122840
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 20 IU oxytocin at a rate of 700 mUI×min(‐1) followed later by 10 UI×h(‐1)
Trial: 23122840
Drug: 100μg bolus
RxNorm normalized name: sulfadimethoxine
DrugBank: Sulfadimethoxine (DB06150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100μg bolus dose of carbetocin
Trial: 19054496
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg intravitreal triamcinolone acetonide (TA)
Trial: 19054496
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg orbital floor triamcinolone acetonide (TA)
Trial: 9006811
Drug: Extended-release gemfibrozil
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended-release gemfibrozil (1200 mg/day) for 3 months
Trial: 9006811
Drug: Regular gemfibrozil
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regular gemfibrozil (1200 mg/day) for 6 months
Trial: 6376209
Drug: Chlorthalidone 50
RxNorm normalized name: chlorthalidone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 50 mg plus triamterene 50 mg
Trial: 22295813
Drug: Distant acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distant acupuncture and nearby tuina therapy (30 treatments)
Trial: 22295813
Drug: Calcium Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium Carbonate D, Tablet (orally for 12 weeks)
Trial: 20814848
Drug: Aliskiren 300
RxNorm normalized name: aliskiren 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg od
Trial: 20814848
Drug: Losartan 100
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 100 mg od
Trial: 11896100
Drug: EU/5-FU (11.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EU/5-FU (11.5 mg/m²/1.15 mg/m² twice daily for 28 days every 35 days)
Trial: 11896100
Drug: 5-FU/LV (425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU/LV (425 mg/m²/20 mg/m² once daily for 5 days every 28 days)
Trial: 27544544
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (2000 IU daily from 26 to 28 weeks of gestation until childbirth)
Trial: 17499406
Drug: Challenge dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Challenge dose of quadrivalent HPV vaccine
Trial: 11601954
Drug: Pharmacologic treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic treatments
Trial: 11601954
Drug: Nonpharmacologic treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacologic treatments
Trial: 22805291
Drug: Trametinib 2
RxNorm normalized name: trametinib 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib 2 mg once daily
Trial: 28732813
Drug: Aspirin with
RxNorm normalized name: Bayer Aspirin with Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin with Curcuma longa
Trial: 28732813
Drug: Aspirin with
RxNorm normalized name: Bayer Aspirin with Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin with Angelica sinensis
Trial: 28732813
Drug: Aspirin with
RxNorm normalized name: Bayer Aspirin with Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin with Panax ginseng
Trial: 25109412
Drug: Immediate-release guanfacine
RxNorm normalized name: guanfacine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release guanfacine (4 mg)
Trial: 25109412
Drug: Immediate-release guanfacine
RxNorm normalized name: guanfacine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release guanfacine (8 mg)
Trial: 23294775
Drug: Fixed-dose design
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose design
Trial: 21410033
Drug: Four-component intravenous
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-component intravenous lipid emulsion (LCT, MCT, Olive-oil and Fish-oil)
Trial: 8546294
Drug: Droperidol (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (1.25 mg) with morphine (1 mg.ml‐1)
Trial: 8546294
Drug: Ondansetron (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (4 mg) with morphine (1 mg.ml‐1)
Trial: 8546294
Drug: Morphine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (1 mg.ml‐1) alone
Trial: 6328297
Drug: oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral acyclovir
Trial: 31250889
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g BCAA
Trial: 31250889
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g BCKA
Trial: 31250889
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g MILK
Trial: 29879719
Drug: Nimodipine plus
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine plus Yufeng Ningxin tablets
Trial: 22429354
Drug: Remifentanil (intravenous)
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil (intravenous)
Trial: 22429354
Drug: Clonidine (intravenous)
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine (intravenous)
Trial: 20124231
Drug: IVIG, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG, 0.5 g/kg
Trial: 12135030
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg budesonide CIR once daily
Trial: 12135030
Drug: 4.5 mg
RxNorm normalized name: phenol 14.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mg budesonide CIR b.i.d.
Trial: 8578018
Drug: Roxithromycin (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin (low dose for a long period of time)
Trial: 7468062
Drug: Heparin (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (5000 units every 12 hours for 10 days)
Trial: 7468062
Drug: Heparin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin + Dihydroergotamine (0.5 mg at the same intervals as heparin)
Trial: 25927298
Drug: Biological measurements
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological measurements including hair and saliva samples.
Trial: 23337477
Drug: lanreotide Autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lanreotide Autogel 60 mg
Trial: 23337477
Drug: lanreotide Autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lanreotide Autogel 90 mg
Trial: 23337477
Drug: lanreotide Autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lanreotide Autogel 90 mg (adjusted according to clinical responses)
Trial: 12038945
Drug: Active lozenge
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active lozenge
Trial: 2665802
Drug: Placebo therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapies
Trial: 339214
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily atenolol (100 mg)
Trial: 339214
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily atenolol (100 mg or 50 mg)
Trial: 25304832
Drug: Preoperative physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative physical activity intervention (PAI) for 6 weeks, including weekly individual face-to-face sessions with tailored instruction in behavioral strategies
Trial: 19820017
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg anastrozole daily
Trial: 16829029
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (200 mcg of selenomethionine daily)
Trial: 11576045
Drug: Naloxone 10
RxNorm normalized name: naloxone 10 mg/0.11 mL nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 10 mg
Trial: 3582483
Drug: Ketotifen syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen syrup 1 mg b.i.d. for 8 days
Trial: 3582483
Drug: Aminophylline syrup
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline syrup 6 mg/kg
Trial: 21445642
Drug: Inhaled sevoflurane
RxNorm normalized name: sevoflurane Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled sevoflurane (group S)
Trial: 21445642
Drug: Intravenous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol (group P)
Trial: 21445642
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (group M)
Trial: 18159096
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and cilostazol (group I, n=141)
Trial: 18159096
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel (group II, n=139)
Trial: 14610641
Drug: Ibandronate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate (2 mg) injections every 3 months plus daily calcium supplements (500 mg)
Trial: 14610641
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral alfacalcidol (1 microg) plus daily calcium supplements (500 mg)
Trial: 3885173
Drug: Combination vindesine
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination vindesine and cisplatin (DDP)
Trial: 3885173
Drug: Single-agent vindesine
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent vindesine (DVA)
Trial: 28671753
Drug: Strategy-A (glucose-dependent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategy-A (glucose-dependent therapies with a non-sulphonylurea OAM and a glucagon-like peptide-1 receptor agonist)
Trial: 28671753
Drug: Strategy-B (non-glucose-dependent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategy-B (non-glucose-dependent therapies with sulphonylurea and insulin glargine)
Trial: 25014995
Drug: Web-based ESRA-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based ESRA-C intervention delivered to patients' homes or to a tablet in clinic.
Trial: 10793318
Drug: Pindolol augmentation
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pindolol augmentation (2.5 mg x 3/d) with paroxetine (60 mg/d)
Trial: 10793318
Drug: Placebo augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo augmentation with paroxetine (60 mg/d)
Trial: 8899094
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg twice daily for 1 week, then once daily for 3 weeks
Trial: 8899094
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg twice daily for 1 week, then once daily for 3 weeks
Trial: 6194757
Drug: Combination antibiotic
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antibiotic therapy (sulbenicillin and amikacin) with S‐sulfonated gamma‐globulin (Group A)
Trial: 6194757
Drug: Combination antibiotic
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antibiotic therapy (sulbenicillin and amikacin) without S‐sulfonated gamma‐globulin (Group B)
Trial: 31566309
Drug: Encorafenib, binimetinib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encorafenib, binimetinib, and cetuximab (triplet-therapy group)
Trial: 31566309
Drug: Encorafenib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encorafenib and cetuximab (doublet-therapy group)